- Home
- FATE vs GLRE Comparison
FATE vs GLRE Comparison
Compare FATE & GLRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FATE
- GLRE
- Stock Information
- Founded
- FATE 2007
- GLRE 2004
- Country
- FATE United States
- GLRE Cayman Islands
- Employees
- FATE N/A
- GLRE N/A
- Industry
- FATE Biotechnology: Biological Products (No Diagnostic Substances)
- GLRE Property-Casualty Insurers
- Sector
- FATE Health Care
- GLRE Finance
- Exchange
- FATE Nasdaq
- GLRE Nasdaq
- Market Cap
- FATE 406.5M
- GLRE 486.3M
- IPO Year
- FATE 2013
- GLRE 2007
- Fundamental
- Price
- FATE $1.27
- GLRE $14.12
- Analyst Decision
- FATE Hold
- GLRE
- Analyst Count
- FATE 10
- GLRE 0
- Target Price
- FATE $6.75
- GLRE N/A
- AVG Volume (30 Days)
- FATE 3.2M
- GLRE 83.9K
- Earning Date
- FATE 02-24-2025
- GLRE 03-04-2025
- Dividend Yield
- FATE N/A
- GLRE N/A
- EPS Growth
- FATE N/A
- GLRE N/A
- EPS
- FATE N/A
- GLRE 2.53
- Revenue
- FATE $13,447,000.00
- GLRE $702,254,000.00
- Revenue This Year
- FATE N/A
- GLRE N/A
- Revenue Next Year
- FATE N/A
- GLRE N/A
- P/E Ratio
- FATE N/A
- GLRE $5.58
- Revenue Growth
- FATE N/A
- GLRE 8.96
- 52 Week Low
- FATE $1.04
- GLRE $11.01
- 52 Week High
- FATE $8.83
- GLRE $15.82
- Technical
- Relative Strength Index (RSI)
- FATE 31.94
- GLRE 51.61
- Support Level
- FATE $1.22
- GLRE $13.42
- Resistance Level
- FATE $1.36
- GLRE $14.31
- Average True Range (ATR)
- FATE 0.15
- GLRE 0.29
- MACD
- FATE -0.02
- GLRE 0.06
- Stochastic Oscillator
- FATE 24.21
- GLRE 78.65
About FATE Fate Therapeutics Inc.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.
About GLRE Greenlight Capital Re Ltd.
Greenlight Capital Re Ltd offers property and casualty reinsurance. Its customers are property and casualty insurers, and Greenlight takes on some of their risk in exchange for insurance premiums. It operates through one operating segment: property and casualty reinsurance. It generates revenue through premiums from reinsurance on property and casualty business assumed, and income from investments.